Will Novo’s LEADER Trial Move GLP-1 To The Front Line In High-Risk Diabetes?

Novo Nordisk sets its sights on GLP-1 expansion after Victoza scores in CV outcomes trial, but docs want the full dataset to understand the robustness and implications of results.

Novo Nordisk AS has an impressive victory with a benefit demonstrated in the LEADER cardiovascular outcomes study of its GLP-1 agonist Victoza in high-risk type 2 diabetes, but the real test could be whether the magnitude of benefit is big enough to shift practice and expand use beyond the class’s tiny base.

The company reported that once-daily Victoza (liraglutide) reduced the cardiovascular event rate compared to standard of care in diabetes patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

Animal Testing: US And EU Regulatory Support Grows For Alternatives, But Validation A Hurdle

 

In this first of a two-part series of articles, US Pharmacopeia CEO Ronald T. Piervincenzi tells the Pink Sheet how the use of alternatives to animal testing in drug development is gaining traction and discusses the challenges that exist.

US FDA ‘Commissioner’s Voucher’ As Public Relations Tool

 

NRx Pharma is trying to capitalize on the headlines about a new US FDA hyper-fast review program, illustrating that the lack of details in the FDA’s announcement is an opening for sponsors to try to grab some attention.